ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 585

Breast Cancer In Systemic Lupus (SLE): Do Demographic and Clinical Factors, Including DNA serology, Influence Risk?

Sasha Bernatsky1, Rosalind Ramsey-Goldman2, Michelle Petri3, Murray B. Urowitz4, Dafna D. Gladman5, Christine Peschken6, William Foulkes1, Yvan St. Pierre7, Patrice Chrétien Raymer7, Basile Tessier Cloutier8, Guillermo Ruiz-Irastorza9, Ann E. Clarke1 and Systemic Lupus International Collaborating Clinics (SLICC)10, 1McGill University, Montreal, QC, Canada, 2Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Johns Hopkins University School of Medicine, Baltimore, MD, 4Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, 5Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 6Medicine & Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 7Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 8Clinical Epidemiology, McGill University, Montreal, QC, Canada, 9Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, 10(coordinating centre), Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Malignancy, serologic tests and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Clinical Aspects I - Renal, Malignancy, Cardiovascular Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose: There is an increase in cancer in SLE over-all, but decrease in other cancers, such as breast cancer. Of particular interest are autoantibodies targeting DNA, which may penetrate cells and interfere with DNA repair; these may be lethal to cancer cells and hence protect against breast cancer. Our primary objective was to assess breast cancer risk in females with SLE, comparing patients who test positive for anti-double stranded (ds) DNA antibodies, versus those who do not. We also assessed other demographic and clinical factors.

Methods: We used data from a very large multi-site international SLE cohort. The data presented in this preliminary analysis are from four centres: Toronto, Montreal, Winnipeg, and Baltimore. We used Cox proportional hazards regression to calculate the hazard ratio (HR) for breast cancer risk in female SLE patients, relative to their exposure in terms of anti-dsDNA positivity over time, in models that controlled for time-dependent medication exposures, demographics (age, race/ethnicity), and calendar year. Anti-dsDNA positivity was assessed on the basis of annual SLE Disease Activity Index, SLEDAI scores, assessed at baseline and annually. A weighted average of the number of times patients were anti-dsDNA positive was generated, and we included in our regression model, a time-dependent variable capturing this weighted average. We also included time-dependent measures of cumulative disease activity (adjusted mean SLEDAI scores, modified by removal of the item for anti-dsDNA). Time zero for the observation interval was SLE diagnosis, so that our analyses adjusted for SLE duration. We included cancers occurring after entry into the lupus cohort and up to the time of cohort exit (defined by death or date of last visit).

Results: These analyses include 34 SLE breast cancers cases and 3,391 female SLE patients without any cancer. Compared to controls without cancer, breast cancer cases tended to be white (78% versus 61% in controls), with a trend towards being older at cohort entry (mean 42.8 years, median 43.6; versus mean 38.4, median 36.8 in controls). The same proportion (20.6%) of cases and cancer-free controls were anti-dsDNA positive at cohort entry, and DNA positivity through the observation interval was also similar. Breast cancer cases were similar to cancer-free controls in terms of baseline disease activity and the profile of cumulative drug exposures over time. In both univariate and multivariate models, the principal factors associated with breast cancer risk were older age at cohort entry and calendar year. Of note, anti-malarial use was not demonstrated as a protective factor in these analyses, modelled either as a categorical or continuous (years exposed) variable.

Conclusion: In these preliminary data, we saw no difference in breast cancer risk in females with SLE, comparing patients who are positive for anti-ds DNA serology, versus those who are not. However, our analyses are based on only 34 cases (and 3,391 controls); as well, we have so far only assessed serology and not specifically cell-penetrating autoantibodies (which may be more important). Our analyses also did not establish anti-malarial agents as protective for breast cancer, but here further analyses are also needed.


Disclosure:

S. Bernatsky,
None;

R. Ramsey-Goldman,
None;

M. Petri,
None;

M. B. Urowitz,
None;

D. D. Gladman,
None;

C. Peschken,
None;

W. Foulkes,
None;

Y. St. Pierre,
None;

P. Chrétien Raymer,
None;

B. Tessier Cloutier,
None;

G. Ruiz-Irastorza,
None;

A. E. Clarke,
None;

S. L. I. C. C. (SLICC),
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/breast-cancer-in-systemic-lupus-sle-do-demographic-and-clinical-factors-including-dna-serology-influence-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology